Bristol Myers Just Crushed Earnings, and the Real Catalyst Hasn’t Even Hit Yet

Bristol Myers Squibb (NYSE:BMY | BMY Price Prediction) reported Q4 2025 revenue of $12.5 billion, essentially flat year-over-year, with full-year 2025 revenue reaching $48.2 billion. The pharmaceutical giant delivered non-GAAP EPS of $1.26 for the quarter, which included a $(0.60) impact from Orbital Therapeutics acquisition charges. The company announced results on Thursday, February 5, 2026, before market open.

Growth Portfolio Drives Performance

Bristol Myers’ Growth Portfolio surged 16% to $7.4 billion in Q4, demonstrating the company’s successful product diversification strategy. Key contributors included Opdivo at $2.69 billion (+9%), Eliquis at $3.45 billion (+8%), and standout performers Breyanzi at $392 million (+49%) and Camzyos at $353 million (+59%).

However, the Legacy Portfolio declined 15% to $5.1 billion as generic competition intensified. Revlimid plummeted 55%, while Sprycel dropped 60%, reflecting the patent cliff challenges facing the company.

Full-Year Results and Outlook

For full-year 2025, Bristol Myers achieved non-GAAP EPS of $6.15, a substantial improvement from prior year levels, with net income of $7.1 billion and gross profit of $34.3 billion.

The company provided 2026 guidance projecting revenue of $46.0 to $47.5 billion, representing a 3% decline at midpoint due to continued legacy portfolio erosion. Management expects non-GAAP EPS of $6.05 to $6.35 with gross margins of 69% to 70%.

CEO Boerner stated the company has “strong momentum in Growth Portfolio, potential for industry-leading sustainable growth into 2030s, data-rich 2026 with multiple pivotal readouts.”

Capital Allocation and Pipeline

Bristol Myers increased its quarterly dividend to $0.63, marking the 17th consecutive annual increase. The company achieved its $10 billion debt paydown ahead of schedule and maintains a $5 billion share repurchase authorization.

Pipeline highlights include Camzyos’ positive Phase 3 results in adolescent HCM, Opdivo’s priority review for treatment of adult and pediatric patients with classical Hodgkin lymphoma, and the launch of Cobenfy in neuroscience. The stock gained 7.7% over the past week and trades near $58.40.